Valion Bio, Inc. VBIO

Valion Bio, Inc. announced leadership and board transitions to strengthen alignment as it advances Entolimod and evaluates strategic opportunities. Dean Zikria, already a board member, has been named Interim Chief Executive Officer to accelerate Entolimod’s clinical progression and pursue commercial and government partnerships. Lisa Wolf continues as President, Chief Operating Officer and Chief Financial Officer. Thomas Jensen was appointed Chair of the Board and the Compensation Committee, succeeding Sheryle Bolton, who stepped down. Jared Malbin becomes Chair of the Audit Committee. The changes aim to sharpen disciplined capital allocation, operational execution and long-term shareholder value while Valion pursues Entolimod milestones and opportunities for Entolasta and other programs, including neutropenia and immune dysfunction. The company’s subsidiary Velocity Bioworks provides CDMO services to support development and manufacturing. Entolimod has FDA Fast Track and Orphan Drug designations; Valion says it is evaluating high-potential opportunities and partnerships, including government programs. Leadership and board realignment aims to sharpen execution and capital allocation, potentially accelerating Entolimod progress and partnerships.

Ukraine's Ministry of Health advances Valion Bio's Entolimod review into technical assessment phase. Regulatory progress on Entolimod opens path to Ukrainian approval and revenue for Valion Bio.

Valion Bio advances government-funded Entolimod radiation injury studies with data expected in early fall. Government-funded Entolimod study advancement and pending data directly support core product development and potential regulatory progress.

Valion Bio, Inc. (VBIO) announces U.S. government-funded Entolimod studies targeting lethal radiation-induced GI injury. Government-funded Entolimod studies signal major validation and funding potential for Valion Bio's core radiation countermeasure program.

Ukraine Ministry of Health accepts Valion Bio's Entolimod dossier for formal review under regulatory equivalence pathway. Entolimod regulatory review acceptance in Ukraine positions VBIO for potential market expansion and revenue growth.

Sheba Medical Center selects Entolimod for clinical trial, potentially expanding Valion Bio into the multi-billion-dollar neutropenia market. Clinical trial selection by Sheba Medical Center opens multi-billion-dollar neutropenia market opportunity for Valion Bio.

Valion Bio advances integrated biodefense and immunology platform through government engagement, domestic manufacturing, and oncology expansion. Government engagement plus manufacturing and oncology expansion signal major strategic moves likely to shift company trajectory.

AFRRI/NIAID created PBI-BM2.5 protocol to test Valion Bio Entolimod as first and only GI-ARS treatment. Protocol positions Entolimod as sole GI-ARS treatment and boosts Valion Bio market trajectory.

Valion Bio confirms U.S. House Armed Services Committee initiative addressing urgent need for radiation and nuclear countermeasures. Government initiative confirmation positions Valion Bio for potential major contracts in nuclear countermeasures development.

Valion Bio briefed senior Department of War and BARDA officials jointly on Entolimod for acute radiation syndrome. High-level government briefings on Entolimod advance prospects for major contracts and regulatory support in radiation countermeasures.

Velocity Bioworks, a subsidiary of Valion Bio, Inc. (VBIO), secured an exclusive commercial license to LarmorBio's BioScan-NMR™ platform, enabling advanced bioprocessing and analytics capabilities. Exclusive license to BioScan-NMR™ platform bolsters VBIO's bioworks innovation and competitive edge in biotech manufacturing.

Valion Bio, Inc. (VBIO) reported first quarter 2026 financial results. Quarterly financial results directly influence VBIO's financial performance and market sentiment.

Valion Bio celebrated the grand opening of the Velocity Bioworks biomanufacturing facility in San Antonio, anchoring domestic production of Entolimod™. Grand opening of domestic biomanufacturing facility secures scalable U.S. production for Entolimod, enabling major strategic growth for VBIO.

Valion Bio receives first FDA-precedent study protocol from NIAID for Entolimod™; federal agency to fully fund BLA-enabling in vivo program and co-navigate FDA submission. NIAID's full funding and co-navigation of Entolimod™ BLA submission provides VBIO with transformative regulatory and financial support toward FDA approval.

Tivic Health Systems, Inc. (TIVC) rebrands as Valion Bio, completing its transformation into a late-stage biopharmaceutical company featuring a government-backed asset and potential multiple revenue streams. Rebranding as Valion Bio completes a pivot to late-stage biopharma with government-backed assets, set to redefine competitive positioning and long-term revenue prospects.

Tivic Health Systems (TIVC) selected to present Entolimod™ as radiation countermeasure and oral transmucosal program plans to Department of War Tech Watch Program on May 7th. Presentation to Department of War Tech Watch on radiation countermeasure represents major strategic pivot toward high-value government contracts with potential to transform revenue trajectory.

Tivic Health Systems, Inc. (TIVC) received a formal request for information from the Ukrainian Ministry of Health regarding strategic stockpiling of Entolimod. Formal government request for strategic stockpiling information on Entolimod indicates potential for major international contract and revenue boost.

Tivic Health Systems, Inc. (TIVC) secured a non-clinical evaluation agreement with NIAID for Entolimod to target Gastrointestinal Acute Radiation Syndrome. NIAID agreement advances TIVC's drug pipeline for radiation syndrome treatments, signaling major strategic progress with potential to elevate market position and investor sentiment.

Tivic Health Systems, Inc. (TIVC) reported full year 2025 results. Full-year financial results represent a major strategic disclosure that can significantly alter investor sentiment and company trajectory.

Tivic Health CEO updates shareholders on Q2 achievements including ClearUP sales growth, new hires in sales and marketing, improved cash position from $1.5M to $3.2M, cost reductions, and optimistic outlook for H2 revenue acceleration amid sinus market opportunities. CEO highlights operational progress, financial improvements, and growth strategies that may moderately boost investor sentiment without transformative changes.

Tivic Health Systems, Inc. (TIVC) appoints biotech veteran Michael K. Handley as CEO to lead strategic expansion into biopharma. Experienced biotech leader's appointment drives major pivot into biopharma, altering strategic trajectory and investor sentiment.

Tivic Health Systems, Inc. is in discussions with the Biomedical Advanced Research and Development Authority (BARDA) regarding the potential use of Entolimod(TM) for treating Acute Radiation Syndrome. This meeting, part of BARDA's TechWatch initiative, aims to explore the drug's capabilities in addressing radiation exposure, particularly in emergency situations. The collaboration could enhance Tivic's position in the biopharmaceutical sector focused on critical health threats. Collaboration with BARDA on a critical health issue like Acute Radiation Syndrome could significantly enhance Tivic's strategic positioning and market opportunities.

Tivic Health Systems, Inc. is set to present its strategic pivot and future plans for advancing Entolimod(TM) towards commercialization at the DealFlow Discovery Conference. The company aims to highlight its progress and vision for the product, which is expected to play a crucial role in its growth strategy. The strategic pivot and focus on advancing Entolimod(TM) could significantly impact Tivic's future performance and market positioning.

Tivic Health Systems, Inc. has achieved a 200x scale-up in the manufacturing of its lead drug candidate, Entolimod(TM), while ensuring reproducible yields, potency, and purity. This advancement positions the company for enhanced production capabilities and potential market competitiveness. The significant scale-up in manufacturing and consistent product quality are likely to enhance Tivic's market position and investor sentiment.

Tivic Health Systems, Inc. announced a special webcast to discuss its recent acquisition of CDMO assets, emphasizing the strategic potential and immediate contributions to accelerating drug development timelines. The acquisition is expected to enhance Tivic's capabilities in drug development and improve operational efficiency. The acquisition of CDMO assets is a significant strategic move that could enhance drug development capabilities and impact future performance.

Tivic Health Systems, Inc. (TIVC) has been highlighted among the most active stocks, indicating increased trading volume and investor interest. The company focuses on developing innovative health solutions, particularly in neuromodulation therapies. Recent market activities suggest a growing recognition of its potential in the healthcare sector, which may influence its stock performance and investor sentiment moving forward. Increased trading activity may moderately influence investor sentiment and market performance.

Tivic Health Systems, Inc. has acquired ready-to-scale cGMP manufacturing and development assets to expedite the commercialization of Entolimod. This strategic move is supported by a financing package exceeding $90 million, positioning Tivic for accelerated growth and enhanced operational capabilities. The acquisition of manufacturing assets and significant financing is likely to significantly impact Tivic's future performance and market positioning.

Tivic Health Systems, Inc. has secured a meeting with the Biomedical Advanced Research and Development Authority (BARDA) to discuss the development of Entolimod(TM) for treating Acute Radiation Syndrome. This meeting is a significant step in advancing the drug's potential use in emergency situations involving radiation exposure, highlighting Tivic's commitment to addressing critical health challenges. Securing a meeting with BARDA indicates a significant opportunity for Tivic to advance its product in a critical health area, potentially impacting its future performance.

Tivic Health Systems, Inc. reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and operational developments. The company continues to focus on advancing its innovative health solutions, aiming to enhance patient care and expand market reach. Management provided insights into future strategies and anticipated challenges, emphasizing a commitment to long-term growth and shareholder value. Revenue growth and operational developments indicate a moderately noticeable influence on financial performance and market positioning.

Tivic Health Systems, Inc. announced the findings of its clinical optimization trial for non-invasive cervical vagus nerve stimulation (ncVNS). The trial aimed to evaluate the efficacy and safety of ncVNS in treating various conditions. Results indicated promising outcomes, suggesting potential benefits for patients and paving the way for further development and commercialization of the technology. The positive trial results could significantly enhance Tivic Health's product offerings and market position in the neuromodulation space.